Soluble TCR Expression Services | TCR & SPR Analysis

Custom Soluble TCR Expression Service Overview

We're pleased to offer specialized custom services related to MHC and T cell receptor research, including the expression of Recombinant T cell receptors, and TCR-related drugs. Researchers often need soluble TCRs to study their role in antigen recognition, develop TCR-based therapies, and screen for therapeutic candidates targeting T cells in complex disease models.

In support of this, we offer custom expression services for Soluble TCR Monomers, fusion proteins, and specialized variants such as His-tagged TCRs. Our platform supports downstream applications such as CAR T cells development, adoptive cell therapy, and antibody-based T cell engagers. Additionally, we provide affinity analysis services including matured. T-cell receptor ELISAs and low affinity surface plasmon resonance (SPR) assays to assess interactions between TCR chains and peptide-loaded MHC complexes.

TCR Expression & Engineering Service Features

Production of various formats of Soluble TCR Monomers, including scFv-TCR, TCR-His, and Fc-fused variants designed for studies involving T cell cytotoxicity and peptide pulsing.

TCR engineering to optimize soluble secretion efficiency structural integrity, and pairing of TCR chains using computational modeling and structure-guided design.

SPR or ELISA analysis of soluble TCR & MHC interactions. Expression in systems like HEK293 cells and CHO-T cells, enabling high-yield recovery, appropriate folding, and post-translational modifications including potential glycosylation sites. Optional purification using Ni column or Protein A column, followed by quality screening for T-cell receptor molecules.

Performance Validation of Expressed TCRs & Affinity Testing

Our Soluble TCR Expression Services can be paired with our advanced surface plasmon resonance (SPR) analysis services, where we perform MHC binding affinity analysis for your TCRs. We also support ELISA-based quantification to characterize T cell activation dynamics in response to defined peptide antigens. Alternatively, you can try our peptide-ready MHC (prMHC) products to load custom peptides such as the peptide SLLMWITQC, MUC1 peptide, or immunodominant NLV peptide onto an MHC monomer or tetramer in-house for customized antigen-presenting cells assays.

If your workflow involves Jurkat T cells, antigen-specific T cells, or T cell clones, let us know in your quote request so we can tailor the solution accordingly. These formats are ideal for screening bispecific T cell engaging TCR constructs, validating antigen-specific T-cell receptor functionality, or analyzing tumor cell surface pHLAs.

Request Quote

Request Quote:

Case Studies & Applications

GP100 TCR & Anti-CD3 Bispecific Fusion

We have successfully expressed a GP100. T cell antigen receptor fused with Anti-CD3, forming a Bispecific T Cell Engager that can simultaneously bind to HLA-A*02:01&B2M&GP100 (YLEPGPVTA) and CD3 heterodimers. This construct demonstrates high binding activity with potential applications in T-cell therapies and immune cells targeting.

Figure 1. In surface plasmon resonance assay, the GP100 TCR & Anti-CD3 Bispecific Fusion can bind to the HLA-A*02:01&B2M&GP100 (YLEPGPVTA) complex tetramer, confirming antigen recognition capacity with an affinity constant of 0.196 nM.

Figure 2. ELISA verification demonstrates that GP100 TCR & Anti-CD3 Bispecific Fusion can bind to HLA-A*02:01&B2M&GP100 (YLEPGPVTA) complex monomer with an EC50 of 11.8 ng/mL.

Figure 3. ELISA verification demonstrates that GP100 TCR & Anti-CD3 Bispecific Fusion can bind to Human CD3E&CD3D, with an EC50 value of 8.7 ng/mL.

Figure 4. ELISA verification demonstrates that GP100 TCR & Anti-CD3 Bispecific Fusion can bind to Human CD3E&CD3G, with an EC50 value of 0.22 μg/mL.

AFP-Specific TCR

We expressed an HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR which can successfully bind to our single-chain trimer MHC-peptide complex and our prMHC loaded with AFP peptide (FMNKFIYEI).

MHC SPR Data on HLA-A*02:01 Monomer & FMNKFIYEI

Figure 5. Single-chain trimer MHC, Human HLA-A*02:01&B2M&AFP (FMNKFIEl) Monomer, His-Avi Tag captured on CM5 Chip via Anti-His Antibody, can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.3991 µM as determined in SPR assay (Biacore T200). This expression was achieved using our mammalian system, with folding efficiency optimized through control of N-linked glycosylation enzymes.

Figure 6. Peptide-ready MHC, Human HLA-A*02:01&B2M, His-Avi Tag loaded with FMNKFIYEI peptide, captured on CM5 Chip via Anti-His Antibody, can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.326 µM as determined in SPR assay (Biacore T200), confirming stable interaction and supporting use in phage display or phage and yeast display platforms.

These studies also support workflows that involve T Cell Mate, LV TCR-T cells, 2A peptide incorporation strategies, or modeling T-cell receptor αβ diversity to improve binding precision and downstream therapeutic utility.

Request Quote

Why Choose KACTUS for TCR Services?

Production of Various TCR Types

We manufacture a range of recombinant T cell receptor (rTCR) formats including Soluble TCR Monomers, scFv-TCRs, and Fc fusions. Our production capabilities support formats applicable in adoptive cell therapy, bispecific T cell engaging TCR research, and T-cell receptor αβ diversity profiling.

TCR Engineering

We apply computational and experimental strategies to optimize T cell receptor expression, pairing of TCR chains, and soluble secretion efficiency. Expression systems like CHO-T cells or HEK293 cells allow for improved folding and scalable yields for therapeutic development.

Affinity Analysis

We provide high-precision analysis of T-cell receptor interactions with antigen-presenting cells using surface plasmon resonance or ELISA. This includes workflows involving rare TCRs like γσ T cells, pp65-specific T cells, or those involved in immunodominant CD8 T cell responses.

Expertise in TCR-MHC interactions

Our experienced team has engineered and tested hundreds of constructs targeting peptide presentation on MHC, including MUC1 peptide, immunodominant NLV peptide, and other tumor-associated epitopes displayed on CHO cell surface or tumor cell surface pHLAs.

Request Quote